{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T22:42:07Z","timestamp":1780872127413,"version":"3.54.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and <jats:italic>R<\/jats:italic> package Bibliometrix.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the <jats:italic>Journal of Clinical Oncology<\/jats:italic>. A total of 37 burst references and five burst references were identified between 2017\u20132022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns.<\/jats:p>","DOI":"10.3389\/fphar.2022.921385","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T16:26:16Z","timestamp":1655742376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiangjun","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.thromres.2013.09.016","article-title":"Tumour Expresion of Tissue Factor and Tissue Factor Pathway Inhibitor in Ovarian Cancer- Relationship with Venous Thrombosis Risk","volume":"132","author":"Abu Saadeh","year":"2013","journal-title":"Thromb. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/s0090-4295(03)00768-4","article-title":"Tissue Factor Expression and Prognosis in Patients with Metastatic Prostate Cancer","volume":"62","author":"Akashi","year":"2003","journal-title":"Urology"},{"key":"B3","first-page":"3862","article-title":"Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: An R-tool for Comprehensive Science Mapping Analysis","volume":"11","author":"Aria","year":"2017","journal-title":"Journal of Informetrics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: a Phase 1 Dose-Escalation and Dose-Expansion Study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-Hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I\/II IMMU-132-01 Basket Trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri2747","article-title":"The Next Generation of Antibody-Drug Conjugates Comes of Age","volume":"10","author":"Beck","year":"2010","journal-title":"Discov. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1472-6890-12-22","article-title":"Trop-2 Protein Overexpression Is an Independent Marker for Predicting Disease Recurrence in Endometrioid Endometrial Carcinoma","volume":"12","author":"Bignotti","year":"2012","journal-title":"BMC Clin. Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-021-06272-x","article-title":"Activity of Trastuzumab Emtansine (T-DM1) in 3D Cell Culture","volume":"188","author":"Boyer","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1185\/03007995.2013.775113","article-title":"Trastuzumab Emtansine (T-DM1) for HER2-Positive Breast Cancer","volume":"29","author":"Boyraz","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"TPS3647","DOI":"10.1200\/jco.2020.38.15_suppl.tps3647","article-title":"EV-202: A Phase II Study of Enfortumab Vedotin in Patients with Select Previously Treated Locally Advanced or Metastatic Solid Tumors","volume":"38","author":"Bruce","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer after Prior HER2-Directed Therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-trop-2\/sn-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized Anti-trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular Cloning of Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas, and Ovarian Cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1471-2407-11-263","article-title":"Expression of Tissue Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for Immunotherapy with hI-Con1, a Factor VII-IgGFc Chimeric Protein Targeting Tissue Factor","volume":"11","author":"Cocco","year":"2011","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired Resistance to Antibody-Drug Conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab Vedotin in Patients with Advanced or Metastatic Solid Tumours (InnovaTV 201): a First-In-Human, Multicentre, Phase 1-2 Trial","volume":"20","author":"De Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/17460441.2021.1858050","article-title":"Current Strategies for the Discovery and Bioconjugation of Smaller, Targetable Drug Conjugates Tailored for Solid Tumor Therapy","volume":"16","author":"Deonarain","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/ph14060498","article-title":"State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-specific Antibody-Drug Conjugates Synthesis","volume":"14","author":"Desligni\u00e8re","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A History of Cancer Chemotherapy","volume":"68","author":"Devita","year":"2008","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab Emtansine versus Capecitabine Plus Lapatinib in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (EMILIA): a Descriptive Analysis of Final Overall Survival Results from a Randomised, Open-Label, Phase 3 Trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of Antibody, Drug and Linker on the Preclinical and Clinical Toxicities of Antibody-Drug Conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"Mabs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II Trial of Labetuzumab Govitecan (Anti-ceacam5\/sn-38 Antibody-Drug Conjugate) in Patients with Refractory or Relapsing Metastatic Colorectal Cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/PGP.0b013e3181ff9234","article-title":"Expression of Tissue Factor and Heparanase in Endometrial Clear Cell Carcinoma: Possible Role for Tissue Factor in Thromboembolic Events","volume":"30","author":"Fadare","year":"2011","journal-title":"Int. J. Gynecol. Pathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing Antibody-Drug Conjugates (ADCs) in HER2-Positive Breast Cancer: State of the Art and Future Directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/cas.13997","article-title":"DLL3 Regulates the Migration and Invasion of Small Cell Lung Cancer by Modulating Snail","volume":"110","author":"Furuta","year":"2019","journal-title":"Cancer Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2007.15.0532","article-title":"Phase I Trial of the Prostate-specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer","volume":"26","author":"Galsky","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.intimp.2019.03.045","article-title":"Bibliometric Analysis of Global Research on PD-1 and PD-L1 in the Field of Cancer","volume":"72","author":"Gao","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to Antibody\u2013Drug Conjugates","volume":"78","author":"Garc\u00eda-Alonso","year":"2018","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-Inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11192-016-1885-6","article-title":"Scientific Workflows for Bibliometrics","volume":"107","author":"Guler","year":"2016","journal-title":"Scientometrics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of Mesothelin in Epithelial Ovarian Cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-small-cell Lung Cancer with an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1395127","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody Structure and Engineering Considerations for the Design and Function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II Randomized Study of Trastuzumab Emtansine versus Trastuzumab Plus Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) Retains All the Mechanisms of Action of Trastuzumab and Efficiently Inhibits Growth of Lapatinib Insensitive Breast Cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular Trafficking of New Anticancer Therapeutics: Antibody-Drug Conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Devel Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/(sici)1097-0215(19980220)79:1<19::aid-ijc4>3.0.co;2-z","article-title":"Tissue-factor Expression in Human Non-small-cell Lung Carcinoma Measured by Immunohistochemistry: Correlation between Tissue Factor and Angiogenesis","volume":"79","author":"Koom\u00e4gi","year":"1998","journal-title":"Int. J. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab Emtansine versus Treatment of Physician's Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): a Randomised, Open-Label, Phase 3 Trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab Emtansine versus Treatment of Physician's Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A Phase II Study of Trastuzumab Emtansine in Patients with Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ddr.21870","article-title":"Recent Advances in Trophoblast Cell-Surface Antigen 2 Targeted Therapy for Solid Tumors","volume":"82","author":"Liao","year":"2021","journal-title":"Drug Dev. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","article-title":"An Open-Label Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of DMUC4064A in Patients with Platinum-Resistant Ovarian Cancer","volume":"163","author":"Liu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The History of Monoclonal Antibody Development - Progress, Remaining Challenges and Future Innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab Emtansine: a Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-positive Cancer","volume":"17","author":"Lorusso","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing Hydrophobicity of Homogeneous Antibody-Drug Conjugates Improves Pharmacokinetics and Therapeutic Index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/19420862.2017.1412130","article-title":"Antibody-drug Conjugates: Design and Development for Therapy and Imaging in and beyond Cancer, LabEx MAbImprove Industrial Workshop, July 27-28, 2017, Tours, France","volume":"10","author":"Martin","year":"2018","journal-title":"Mabs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/pharmaceutics13101705","article-title":"Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives","volume":"13","author":"Mart\u00edn-Sabroso","year":"2021","journal-title":"Pharmaceutics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, Randomized Trial of Mirvetuximab Soravtansine versus Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer: Primary Analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/DDDT.S240854","article-title":"Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date","volume":"15","author":"Moussa","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","article-title":"Safety and Pharmacokinetics of MM-302, a HER2-Targeted Antibody-Liposomal Doxorubicin Conjugate, in Patients with Advanced HER2-Positive Breast Cancer: a Phase 1 Dose-Escalation Study","volume":"119","author":"Munster","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s12094-021-02707-5","article-title":"Antibody-drug Conjugate as Targeted Therapeutics against Hepatocellular Carcinoma: Preclinical Studies and Clinical Relevance","volume":"24","author":"Murali","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel Antibody Drug Conjugates Containing Exatecan Derivative-Based Cytotoxic Payloads","volume":"26","author":"Nakada","year":"2016","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of Mesothelin Immunostaining in Tumor Diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an Emerging Target in Small Cell Lung Cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-Drug Conjugates: The New Frontier of Chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.semcancer.2019.12.024","article-title":"Antibody-drug Conjugates for Lung Cancer in the Era of Personalized Oncology","volume":"69","author":"Ricciuti","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/(sici)1097-0215(19980529)76:5<671:aid-ijc10>3.0.co;2-7","article-title":"Human Trop-2 Is a Tumor-Associated Calcium Signal Transducer","volume":"76","author":"Ripani","year":"1998","journal-title":"Int. J. Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma after Platinum and Anti-programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-021-06267-8","article-title":"Chemotherapy-related Amenorrhea (CRA) after Adjuvant Ado-Trastuzumab Emtansine (T-DM1) Compared to Paclitaxel in Combination with Trastuzumab (TH) (TBCRC033: ATEMPT Trial)","volume":"189","author":"Ruddy","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"B76","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-Targeted Antibody-Drug Conjugate Eradicates High-Grade Pulmonary Neuroendocrine Tumor-Initiating Cells In Vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich's Magic Bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","article-title":"Conjugation Site Modulates the In Vivo Stability and Therapeutic Activity of Antibody-Drug Conjugates","volume":"30","author":"Shen","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2021.10.006","article-title":"Antibody Drug Conjugates in Gastrointestinal Cancer: From Lab to Clinical Development","volume":"340","author":"Singh","year":"2021","journal-title":"J. Control Release"},{"key":"B80","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COC.0000000000000816","article-title":"Cost-effectiveness Analysis of Ado-Trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients with Residual Invasive HER2+ Early Breast Cancer in the United States","volume":"44","author":"Sussell","year":"2021","journal-title":"Am. J. Clin. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1002\/ijc.32408","article-title":"[fam-] Trastuzumab Deruxtecan, Antitumor Activity Is Dependent on HER2 Expression Level rather Than on HER2 Amplification","volume":"145","author":"Takegawa","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-Positive Breast Cancer Previously Treated with Trastuzumab Emtansine: a Dose-Expansion, Phase 1 Study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 Quantitatively Stimulates Human Cancer Growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant Intracellular Metabolism of T-DM1 Confers T-DM1 Resistance in Human Epidermal Growth Factor Receptor 2-positive Gastric Cancer Cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential Drugs Used in the Antibody-Drug Conjugate (ADC) Architecture for Cancer Therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J. Cell Physiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab Vedotin after PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (EV-201): a Multicentre, Single-arm, Phase 2 Trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 Alterations in Non-small-cell Lung Cancer: A Comprehensive Review","volume":"4","author":"Zhao","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/bc400490z","article-title":"Production of Site-specific Antibody-Drug Conjugates Using Optimized Non-natural Amino Acids in a Cell-free Expression System","volume":"25","author":"Zimmerman","year":"2014","journal-title":"Bioconjug Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.921385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T16:26:21Z","timestamp":1655742381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.921385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":92,"alternative-id":["10.3389\/fphar.2022.921385"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.921385","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"article-number":"921385"}}